Day: February 5, 2024

WASHINGTON, Feb. 05, 2024 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that it will release financial results for the fourth quarter and full year ended December 31, 2023, before the New York market opens on Thursday, February 22, 2024. A conference call will be held to discuss these financial results on Thursday, February 22, 2024, at 9:00 a.m. Eastern Time and will be hosted by senior management. The conference call will be simulcast live on the Internet and can be accessed by logging onto the Company’s investor relations website. A replay of the webcast will be available on the Company’s investor relations website for 90 days. About FTI ConsultingFTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial,...

On 15 November 2023, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 14 of 14 November 2023. Under the programme Schouw & Co. will acquire shares for up to DKK 75 million during the period 15 November 2023 to 1 March 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 26/1/2024 93,100 543.59 50,608,243    Monday, 29 January 2024 1,700 555.93 945,081    Tuesday, 30 January 2024 1,700 554.72 943,024    Wednesday, 31 January 2024 1,700 553.57 941,069    ...

Today, Terranet is opening a new office on Lindholmen in Gothenburg. Lindholmen is known as one of Sweden’s most dynamic innovation hubs, particularly within the automotive industry, offering a unique environment where technological development, research, and business opportunities converge. The new office puts Terranet in the heart of an ecosystem comprised of key players in the automotive industry, including suppliers, technology innovators, and vehicle manufacturers. The location is strategically chosen and is expected to enhance the company’s ability to progress crucial connections in the industry, explore new collaborations, and establish meaningful partnerships.By establishing an office on Lindholmen, we will be geographically closer to potential partners and customers. We look forward to bringing Terranet to Gothenburg...

TORONTO and MANCHESTER, England, Feb. 05, 2024 (GLOBE NEWSWIRE) — Onex Corporation (“Onex”) (TSX: ONEX) today announced that Onex Partners V has completed a majority investment in Morson Group (“Morson” or the “Company”), a leading UK engineering and technical staffing and workforce solutions business, with growing operations in the UK, U.S., Italy, Canada and Australia. The investment has been made alongside the founding family CEO Ged Mason and members of the management team. Financial terms were not disclosed. Headquartered in Manchester, United Kingdom, Morson Group provides services including: (i) contingent workforce solutions, relating to the placement of engineering, IT and technical contractors with customers, (ii) permanent recruitment and recruitment process outsourcing (RPO), (iii) related planning workforce support...

— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded data from the ongoing Phase 2 clinical trial of the Company’s lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease (“cLDD”). The presented poster, titled “Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease; Initial Phase 2 Clinical Safety and Feasibility...

CARLSBAD, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its second United States Patent No: 11,850,162 entitled “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use” for The World’s First DEXA Technology™ Patient-Matched Implant Technology. Aurora Spine’s first-of-its kind DEXA Technology™ is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure and bone support. This patent will be utilized to create implants that match the patient’s specific bone density based on a DEXA Scan/T-score allowing for the best bone fusion treatment and most favorable...

ROGERS, Ark., Feb. 05, 2024 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2024 third quarter financial results on Friday, March 8, 2024, before the market opens and senior management will host a conference call at 11:00 a.m ET to discuss the results. Participants may access the conference call via webcast using this link: Webcast Link Here. To participate via telephone, please register in advance using this Registration Link. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. All participants are encouraged to dial-in 10 minutes prior to the start time. A replay of the conference call and webcast will be available...

88 patients enrolledJanuary being the highest enrollment month since the launch of TigrisTORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment:Robust enrollment activity continues throughout 2024:88 patients enrolled to-dateSix patients enrolled in the month of January, which is the highest monthly enrollment experienced since the start of the Tigris study One patient enrolled in February to dateClosing in on the interim enrollment target of...

Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law WEST CHESTER, Pa., Feb. 05, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has filed a lawsuit in the Eastern District of Pennsylvania against Dormer Laboratories Inc., a Canada corporation (“Dormer Labs”) requesting, among other relief, that the court enjoin Dormer Labs from marketing, selling, and distributing drugs containing cantharidin in the United States, as well as compensatory, statutory and punitive damages for Dormer Labs’ violations of the federal Lanham Act and Pennsylvania...